Victoza Approved In China: Novo Nordisk Gears Up To Conquer China's Diabetes Market
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Denmark's Novo Nordisk AS announced March 15 that its human glucagon-like peptide-1 (GLP-1) analogue Victoza (liraglutide) was granted regulatory approval from China's State FDA, and plans to launch the anti-diabetes drug in the second half of this year
You may also be interested in...
China Ramps Up Diagnostics Efforts To Deal With Diabetes Surge; Mandates Screening For At-risk Populations
China will enact regulations to mandate regular screening for diabetes among high-risk populations, which could spur a surge in demand for diabetes treatments and diagnostic devices that dwarfs that of the United States.
Emerging Markets Earnings Roundup: Merck And Novo Nordisk
In this earnings round up, we zoom in on Merck and Novo Nordisk’s performance in emerging markets for 2012.
Emerging Markets Earnings Roundup: Merck And Novo Nordisk (Part 5)
In this earnings round up, we zoom in on Merck and Novo Nordisk performance in emerging markets for 2012.